Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL20638631 | 0.91 | ROCK2 (0.67) | ROCK2 | |
| SCHEMBL19128905 | 0.88 | ROCK2 (0.66) | ROCK2 | |
| SCHEMBL19128848 | 0.87 | ROCK2 (0.72) | ROCK2 | |
| SCHEMBL19127968 | 0.87 | ROCK2 (0.71) | ROCK2 | |
| SCHEMBL24247701 | 0.85 | ROCK2 (0.73) | ROCK2 | |
| SCHEMBL19127334 | 0.85 | ROCK2 (0.64) | ROCK2 | |
| SCHEMBL19128500 | 0.85 | ROCK2 (0.77) | ROCK2 | |
| SCHEMBL19128826 | 0.85 | ROCK2 (0.65) | ROCK2 | |
| Formamide SCHEMBL20638677 | 0.84 | ROCK2 (0.70) | ROCK2 | |
| SCHEMBL20647064 | 0.84 | ROCK2 (0.74) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.